drugset / Trial / NCT00800319
ALK33-001: A Study of RDC-0313 Administered to Healthy Adults
RandomizedSingle-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the pharmacokinetics, safety, and tolerability of RDC-0313 following oral administration.
Timeline
- Start
- 2008-12
- Primary completion
- 2009-02
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Samidorphan | Small molecule | 5 mg | Oral |
| Subject | Samidorphan | Small molecule | 15 mg | Oral |
| Subject | Samidorphan | Small molecule | 25 mg | Oral |
| Subject | Samidorphan | Small molecule | 50 mg | Oral |
| Subject | Samidorphan | Small molecule | 75 mg | Oral |